| [1] |
Robertson JG.Enzymes as a special class of therapeutic target:clinical drugs and modes of action[J].Curr Opin Struct Biol,2007,17(6):674-679.
|
| [2] |
Robertson JG.Mechanistic basis of enzyme-targeted drugs[J].Biochemistry,2005,44(15):5561-5571.
|
| [3] |
Singh J,Petter RC,Baillie TA,et al. The resurgence of covalent drugs[J].Nat Rev Drug Discov,2011,10(4):307-317.
|
| [4] |
Johnson DS,Weerapana E,Cravatt BF.The synthesis of possible transition state analogue inhitors of thymidine phosphorylase[J].Future Med Chem,2015(56):406-409.
|
| [5] |
Kwak EL,Sordella R,Bell DW, et al.Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J].Proc Natl Acad Sci U S A,2005,102(21):7665-7670.
|
| [6] |
Butterworth S,Finlay MRV,Ward RA,et al.2-(2,4,5-Substituted-anilino)pyrimidine derivatives as EGFR modulators useful for treating cancer:WO,2013014448A[P].2012-01-31[2016-01-06] .
|
| [7] |
U. S. Food and Drug Administration. Osimertinib[EB/OL].http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm.
|
| [8] |
Ou SH. Second-generation irreversible epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs):a better mousetrap? A review of the clinical evidence[J].Crit Rev Oncol Hematol,2012,83(3):407-421.
|
| [9] |
Honigberg LA,Smith AM,Sirisawad M,et al.The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy[J].Proc Natl Acad Sci U S A,2010,107(29):13075-13080.
|
| [10] |
Liu Q,Sabnis Y,Zhao Z,et al.Developing irreversible inhibitors of the protein kinase cysteinome[J].Chem Biol,2013,20(2):146-159.
|
| [11] |
Huang F, Zhu HJ, Zhou X, et al. Progress of bruton′s tyrosine kinase(BTK)and its inhibitors[J].J China Pharm Univ(中国药科大学学报),2014,45(6):617-624.
|
| [12] |
Li D,Ambrogio L,Shimamura T,et al.BIBW2992,an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models[J].Oncogene,2008,27(34):4702-4711.
|
| [13] |
Giordano P,Manzo A,Montanino A,et al.Afatinib:an overview of its clinical development in non-small-cell lung cancer and other tumors[J].Crit Rev Oncol Hematol,2016,97:143-151.
|
| [14] |
Rabindran SK,Discafani CM,Rosfjord EC,et al.Antitumor activity of HKI-272,an orally active,irreversible inhibitor of the HER-2 tyrosine kinase[J].Cancer Res,2004,64(11):3958-3965.
|
| [15] |
Schwab CL,English DP,Black J,et al.Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo[J].Gynecol Oncol,2015,139(1):112-117.
|
| [16] |
Korfage IJ,Essink-Bot ML,Westenberg SM,et al.How distressing is referral to colposcopy in cervical cancer screening[J]?Gynecol Oncol,2014,132(1):142-148.
|
| [17] |
Becker D,Walters Haygood CL,Smith B,et al.Survival and toxicity of a modified GOG 172 IP chemotherapy regimen in patients with ovarian,fallopian tube or primary peritoneal carcinoma[J].Gynecol Oncol,2015,137(1):176-177.
|
| [18] |
Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804,an irreversible pan-erbB inhibitor,is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib[J].Cancer Res,2007,67(24):11924-11932.
|
| [19] |
Gonzales AJ,Hook KE,Althaus IW,et al.Antitumor activity and pharmacokinetic properties of PF-00299804,a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor[J].Mol Cancer Ther,2008,7(7):1880-1889.
|
| [20] |
Matsuyama A,Arai R,Yashiroda Y,et al.ORFeome cloning and global analysis of protein localization in the fission yeast Schizosaccharomyces pombe[J].Nat Biotechnol,2006,24(7):841-847.
|
| [21] |
Evans E,Ponader S,Karp R,et al.Covalent inhibition of btk with clinical development compound AVL-292 disrupts signaling that maintains the microenvironment necessary for chronic lymphocytic leukemia growth[J].Cl Lymph Myelom Leuk,2011,11(2):S173-S174.
|
| [22] |
Wu H,Wang WC,Liu FY,et al.Discovery of a potent,covalent BTK inhibitor for B-cell lymphoma[J].ACS Chem Biol,2014,9(5):1086-1091.
|
| [23] |
Janssen I.A study to investigate the effects of itraconazole on the pharmacokinetics of JNJ-42165279 in healthy male participants [EB/OL].https://www.clinicaltrials.gov/ct2/show/NCT02065739.
|
| [24] |
Fouqué A,Delalande O,Jean M,et al. A novel covalent mTOR inhibitor,DHM25,shows in vivo antitumor activity against triple-negative breast cancer cells[J].J Med Chem,2015,58(16):6559-6573.
|
| [25] |
Peto R,Davies C,Godwin,et al.Comparisons between different polychemotherapy regimens for early breast cancer:meta-analyses of long-term outcome among 100,000 women in 123 randomised trials[J].Lancet,2012,379(9184):432-444.
|
| [26] |
Malleter M,Tauzin S,Bessede A,et al.CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer[J].Cancer Res,2013,73(22):6711-6721.
|
| [27] |
Zhou W, Hur W, McDermott U, et al. A structure-guided approach to creating covalent FGFR inhibitors[J].Chem Biol,2010,17(3):285-295.
|
| [28] |
Zhang T,Inesta-vaquera F,Niepel M,et al.Discovery of potent and selective covalent inhibitors of JNK[J].Chem Biol,2010,19(1):140-154.
|
| [29] |
Leproult E,Barluenga S,Moras D,et al.Cysteine mapping in conformationally distinct kinase nucleotide binding sites:application to the design of selective covalent inhibitors[J].J Med Chem,2011,54(5):1347-1355.
|
百度学术
下载:
